LP
Lucid Peptides
Research Grade

Research Summary

IGF-1 LR3

Research Hub
Clinical — 10 studies

IGF-1 LR3 is a modified insulin-like growth factor studied for its extended half-life and receptor binding properties.

Being studied for

IGF-1 signaling researchCell growth and proliferation pathways

Published Research

Evidence profile

Controlled human evidence

10 cited publications · 1 primary trial

Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.

Supporting evidence

ClinicalPrimary trial

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL et al. · The Journal of clinical endocrinology and metabolism · 2006

The study reportedSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses.

PMID 16352683DOI 10.1210/jc.2005-1536
View on PubMed
ReviewMeta-analysis

Place of cabergoline in acromegaly: a meta-analysis

Sandret L et al. · The Journal of clinical endocrinology and metabolism · 2011

The study reportedThis meta-analysis suggests that cabergoline single-agent therapy normalizes IGF-I levels in one third of patients with acromegaly. When a somatostatin analog fails to control acromegaly, cabergoline adjunction normalizes IGF-I in about 50% of cases. This effect may occur even in patients with normoprolactinemia.

PMID 21325455DOI 10.1210/jc.2010-2443
View on PubMed
Additional indexed literature (8)

Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.

View full peptide profile for IGF-1 LR3
All Research
[Notice]All information on this page is provided strictly for laboratory research and educational purposes only.